PTCL and cutaneous T-cell lymphoma (CTCL) are also disease groups with effective HDAC inhibitors, empirically interpreted as HDAC activation. The gene discussed is HDAC9; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.